NGDN and endometrial cancer: Although metformin has been noted to act through alteration of AMPK/mTOR, K-Ras, and the eIF4E-binding protein in diabetic patients and cancer cells [22, 23, 38, 39], the precise mechanisms for its inhibition of endometrial cancer are not yet fully understood.